NasdaqGS:MDGLBiotechs
Madrigal Revenue Beats Highlight Rezdiffra Momentum And Investor Trade Offs
Madrigal Pharmaceuticals reported strong fourth quarter revenue, supported by demand for its new MASH therapy, Rezdiffra.
Rezdiffra adoption is gaining traction in the commercial rollout, contributing to revenue that surpassed earlier expectations.
Analysts have responded positively to the results, reflecting increased confidence in Madrigal’s commercial path for NasdaqGS:MDGL.
Madrigal Pharmaceuticals, trading as NasdaqGS:MDGL, is drawing fresh attention after upbeat fourth quarter results...